A systematic review of St. John's wort for major depressive disorder

Systematic Reviews

Volumn 5, Issue 1, 2016, Pages

  Apaydin, Eric A ^a   Maher, Alicia R ^b   Shanman, Roberta ^a   Booth, Marika S ^a   Miles, Jeremy N V ^a   Sorbero, Melony E ^a   Hempel, Susanne ^a  

^a RAND CORPORATION   (United States)

^b Akasha Center for Integrative Medicine   (United States)

Author keywords

Antidepressant; Complementary and alternative medicine; Herb; Major depressive disorder; Meta analysis; St. John's wort; Systematic review

Indexed keywords

ANTIDEPRESSANT AGENT; HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT;

ARTICLE; BIBLIOGRAPHIC DATABASE; BIPOLAR DISORDER; CARDIOVASCULAR DISEASE; COMPARATIVE EFFECTIVENESS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSTHYMIA; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; META ANALYSIS (TOPIC); MONOTHERAPY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUERPERAL DEPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SKIN DISEASE; SYSTEMATIC REVIEW; ALTERNATIVE MEDICINE; HYPERICUM; META ANALYSIS; TREATMENT OUTCOME; UTILIZATION;

ANTIDEPRESSIVE AGENTS; COMPLEMENTARY THERAPIES; DEPRESSIVE DISORDER, MAJOR; HUMANS; HYPERICUM; TREATMENT OUTCOME;

EID: 84985029383     PISSN: None     EISSN: 20464053     Source Type: Journal    
DOI: 10.1186/s13643-016-0325-2     Document Type: Article

References (56)

1. World Health Organization. Depression (fact sheet N. 369). vol. 5; 2012: 2013
2. Center for Behavioral Health Statistics and Quality. Behavioral health trends in the United States: results from the 2014 National Survey on Drug Use and Health. 2015, NSDUH Series H-50(HHS Publication No. SMA 15-4927)
3. Pratt LA, Brody DJ. Depression in the U.S. household population, 2009-2012. Hyattsville: National Center for Health Statistics; 2014.
4. Stewart WF, Ricci JA, Chee E, Hahn SR, Morganstein D. Cost of lost productive work time among us workers with depression. JAMA. 2003;289(23):3135-44.
5. Linde K, Kriston L, Rücker G, Jamil S, Schumann I, Meissner K, Sigterman K, Schneider A. Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis. Ann Fam Med. 2015;13(1):69-79.
6. Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev. 2008;4:CD000448.
7. Knuppel L, Linde K. Adverse effects of St. John's wort: a systematic review. J Clin Psychiatry. 2004;65(0160-6689 (Print)):1470-9.
8. Liu FF, Ang CY, Heinze TM, Rankin JD, Beger RD, Freeman JP, Lay Jr JO. Evaluation of major active components in St. John's wort dietary supplements by high-performance liquid chromatography with photodiode array detection and electrospray mass spectrometric confirmation. J Chromatogr A. 2000;888(1-2):85-92.
9. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
10. US Preventative Services Task Force. US Preventive Services Task Force Procedure Manual. Rockville, MD; 2008
11. Lewin Group and ECRI Institute. Management of dyslipidemia: evidence synthesis report. Clinical Practice Guideline. Washington, DC: Veterans Health Administration, U.S. Department of Veterans Affairs and the U.S. Department of Defense; 2014
12. Hartung J. An alternative method for meta-analysis. Biom J. 1999;41(8):901-16.
13. Hartung J, Knapp G. A refined method for the meta-analysis of controlled clinical trials with binary outcome. Stat Med. 2001;20(24):3875-89.
14. Sidik K, Jonkman JN. Robust variance estimation for random effects meta-analysis. Comput Stat Data Anal. 2006;50(12):3681-701.
15. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401-6.
16. Bernhardt M LE, Ebeling L. Hypericum perforatum in therapy of mild to moderate depressive moods [Hypericum perforatum in der Therapie leichter bis mittelschwerer Depressive Verstimmungen]. Phytotherapiekongreβ 1993, Abstracts 5(Bonn 5.-6.)
17. Behnke K, Jensen GS, Graubaum HJ, Gruenwald J. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression. Adv Ther. 2002;19(1):43-52.
18. Bjerkenstedt L, Edman GV, Alken RG, Mannel M. Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients. Eur Arch Psychiatry Clin Neurosci. 2005;255(1):40-7.
19. Brenner R, Azbel V, Madhusoodanan S, Pawlowska M. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Clin Ther. 2000;22(4):411-9.
20. Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, Murck H, Rosenbaum JF. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol. 2005;25(5):441-7.
21. Gastpar M, Singer A, Zeller K. Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. Pharmacopsychiatry. 2005;38(2):78-86.
22. Gastpar M, Singer A, Zeller K. Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. Pharmacopsychiatry. 2006;39(2):66-75.
23. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002;287(14):1807-14.
24. Harrer G, Hübner WD, Podzuweit H. Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotiline: a multicenter double-blind study. J Geriatr Psychiatry Neurol. 1994;7(1):S24-8.
25. Harrer G, Schmidt U, Kuhn U, Biller A. Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine [Äquivalenzvergleich Johanniskraut-Extrakt LoHyp-57 versus Fluoxetin]. Arzneimittelforschung. 1999;49(4):289-96.
26. Kalb R, Trautmann-Sponsel RD, Kieser M. Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients. A randomized double-blind multicenter clinical trial. Pharmacopsychiatry. 2001;34(3):96-103.
27. Kasper S, Anghelescu IG, Szegedi A, Dienel A, Kieser M. Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]. BMC Med. 2006;4:14.
28. Kasper S, Volz HP, Moller HJ, Dienel A, Kieser M. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression-a double-blind, randomized, placebo controlled long-term trial. Eur Neuropsychopharmacol. 2008;18(11):803-13.
29. Laakmann G, Dienel A, Kieser M. Clinical significance of hyperforin for the efficacy of Hypericum extracts on depressive disorders of different severities. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology. 1998;5(6):435-42.
30. Lecrubier Y, Clerc G, Didi R, Kieser M. Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry. 2002;159(8):1361-6.
31. Lenoir S, Degenring FF, Saller R. A double-blind randomised trial to investigate three different concentrations of a standardised fresh plant extract obtained from the shoot tips of Hypericum perforatum L. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology. 1999;6(3):141-6.
32. Liu J, Meng ZW, Li LY, Feng LS, Yang H. Effect of St. John's wort extract on depressive disorder in elderly patients with unstable angina. World Journal of Emergency Medicine. 2010;1(1):41-4.
33. Mannel M, Kuhn U, Schmidt U, Ploch M, Murck H. St John's wort extract LI160 for the treatment of depression with atypical features-a double-blind, randomized, and placebo-controlled trial. J Psychiatr Res. 2010;44(12):760-7.
34. Montgomery S, Hubner W, Grigoleit H. Efficacy and tolerability of St. John's wort extract compared with placebo in patients with a mild to moderate depressive disorder. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology. 2000;7(2):107.
35. Moreno RA, Teng CT, Almeida KM, Tavares Junior H. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: a randomized double-blind trial in a Brazilian sample. Rev Bras Psiquiatr. 2006;28:29-32.
36. Pakseresht S, Boustani H, Azemi ME, Nilsaz J, Babapour R, Haghdust MR. Evaluation of pharmaceutical products of St. John's wort efficacy added on tricyclic antidepressants in treating major depressive disorder: a double blind randomized control trial. Jundishapur Journal of Natural Pharmaceutical Products. 2012;7(3):106-10.
37. Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. BMJ. 1999;319(7224):1534-8.
38. Rahman R, Ansari MA, Hayder Z, Siddiqui AA, Bukhari IA, Qayyum MA. Double blind placebo controlled clinical trial examining the effectiveness of St. John's wort (hypericum perforatum) in mild to moderate depression. J Pak Psych Soc. 2008;5:105-11.
39. Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol. 2000;15(2):61-8.
40. Schrader E, Meier B, Brattström A. Hypericum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multicentre study. Human Psychopharmacology: Clinical & Experimental. 1998;13(3):163-9.
41. Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME, Russell J, Lydiard RB, Crits-Cristoph P, Gallop R, et al. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA. 2001;285(15):1978-86.
42. Szegedi A, Kohnen R, Dienel A, Kieser M. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine. BMJ. 2005;330(7490):503.
43. Uebelhack R, Gruenwald J, Graubaum HJ, Busch R. Efficacy and tolerability of hypericum extract STW 3-VI in patients with moderate depression: a double-blind, randomized, placebo-controlled clinical trial. Adv Ther. 2004;21(4):265-75.
44. Vorbach EU, Arnoldt KH, Hubner WD. Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry. 1997;30 Suppl 2:81-5
45. Wheatley D. LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients-a controlled 6-week clinical trial. Pharmacopsychiatry. 1997;30 Suppl 2:77-80
46. Woelk H. Comparison of St John's wort and imipramine for treating depression: randomised controlled trial. BMJ. 2000;321(7260):536-9.
47. van Gurp G, Meterissian G, Haiek L, McCusker J, Bellavance F. St John's wort or sertraline? Randomized controlled trial in primary care. Can Fam Physician. 2002;48(905):905-12.
48. Hansgen K, Vesper J, Ploch M. Multicenter double-blind study examining the antidepressant effectiveness of the hypericum extract LI 160. J Geriatr Psychiatry Neurol. 1994;7 Suppl 1:S15-8.
49. Witte B, Harrer G, Kaptan T, Podzuweit H, Schmidt U. Treatment of depressive symptoms with a high concentration hypericum preparation. A multicenter placebo-controlled double-blind study [Behandlung depressiver Verstimmungen mit einem hochkonzentrierten Hypericumpräparat: Eine multizentrische plazebokontrollierte Doppelblindstudie.]. Fortschr Med. 1995;113(28):404-8.
50. Volz HP, Eberhardt R, Grill G. Efficacy and tolerance of the St John's wort extract D-0496 in mild to moderate depression-a placebo-controlled, double-blind 6-week trial [Wirksamkeit und Verträglichkeit des Johanniskrautextraktes D-0496 bei leichten bis mittelschweren depressiven Episoden. Plazebokontrollierte Doppelblindstudie über 6 Wochen]. Nervenheilkunde. 2000;19:401-5.
51. National Institute for Health and Clinical Excellence. Depression in adults: recognition and management. NICE Guidelines. 2009
52. Rahimi R, Abdollahi M. An update on the ability of St. John's wort to affect the metabolism of other drugs. Expert Opin Drug Metab Toxicol. 2012;8(6):691-708.
53. Nadkarni A, Oldham MA, Howard M, Berenbaum I. Drug-drug interactions between warfarin and psychotropics: updated review of the literature. Pharmacotherapy. 2012;32(10):932-42.
54. Tsai HH, Lin HW, Simon Pickard A, Tsai HY, Mahady GB. Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review. Int J Clin Pract. 2012;66(11):1056-78.
55. Hoban CL, Byard RW, Musgrave IF. A comparison of patterns of spontaneous adverse drug reaction reporting with St. John's wort and fluoxetine during the period 2000-2013. Clin Exp Pharmacol Physiol. 2015;42(7):747-51.
56. Bracher A. Trial on HYP611 confirms effectiveness [HYP611-Studie bestätigt Wirksamkeit]. Ärztliche Praxis 2001